Trial Profile

KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Vibostolimab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms MK-3475-01A; MK-3475-01A/KEYNOTE-01A
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

22 May 2025 According to Daiichi Sankyo Company media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25)
01 May 2025 Planned End Date changed from 13 Feb 2039 to 13 Feb 2032.
01 May 2025 Planned primary completion date changed from 13 Feb 2039 to 13 Feb 2032.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com